Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × OTHER_GOV × famitinib × Clear all

Phase

Status

Sponsor Class

OTHER 2 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Cyclophosphamide 3 Cisplatin 3 pembrolizumab 2 fludarabine 2 apatinib 2 XELOX 2 S 1 (combination) 2 Oxaliplatin 2 Nivolumab 2 Irinotecan 2 Gemcitabine 2 Fulvestrant 2 Drug Therapy 2 titanium silicide 1 tislelizumab 1 surufatinib 1 sintilimab 1 pegfilgrastim 1 nimotuzumab 1 ipatasertib 1 ferumoxides 1 famitinib 1 eribulin 1 dalpiciclib 1 dactolisib 1 capivasertib 1 camrelizumab 1 aldesleukin 1 Tramadol 1 Tai Ji 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05176080 2024-12-17

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Henan Cancer Hospital

Phase 1/2 Terminated

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡